Leong Samuel Liwei, Murdolo Lawton, Maddumage Janesha C, Koutsakos Marios, Kedzierska Katherine, Purcell Anthony W, Gras Stephanie, Grant Emma J
Infection and Immunity Program, La Trobe Institute for Molecular Science (LIMS) La Trobe University Bundoora VIC Australia.
Department of Biochemistry and Chemistry, School of Agriculture, Biomedicine and Environment (SABE) La Trobe University Bundoora VIC Australia.
Clin Transl Immunology. 2024 May 10;13(5):e1509. doi: 10.1002/cti2.1509. eCollection 2024.
Seasonal influenza viruses cause roughly 650 000 deaths annually despite available vaccines. CD8 T cells typically recognise influenza-derived peptides from internal structural and non-structural influenza proteins and are an attractive avenue for future vaccine design as they could reduce the severity of disease following infection with diverse influenza strains. CD8 T cells recognise peptides presented by the highly polymorphic Human Leukocyte Antigens class I molecules (HLA-I). Each HLA-I variant has distinct peptide binding preferences, representing a significant obstacle for designing vaccines that elicit CD8 T cell responses across broad populations. Consequently, the rational design of a CD8 T cell-mediated vaccine would require the identification of highly immunogenic peptides restricted to a range of different HLA molecules.
Here, we assessed the immunogenicity of six recently published novel influenza-derived peptides identified by mass-spectrometry and predicted to bind to the prevalent HLA-B*18:01 molecule.
Using CD8 T cell activation assays and protein biochemistry, we showed that 3/6 of the novel peptides were immunogenic in several HLA-B18:01 individuals and confirmed their HLA-B18:01 restriction. We subsequently compared CD8 T cell responses towards the previously identified highly immunogenic HLA-B18:01-restricted NP peptide. Using X-ray crystallography, we solved the first crystal structures of HLA-B18:01 presenting immunogenic influenza-derived peptides. Finally, we dissected the first TCR repertoires specific for HLA-B*18:01 restricted pathogen-derived peptides, identifying private and restricted repertoires against each of the four peptides.
Overall the characterisation of these novel immunogenic peptides provides additional HLA-B*18:01-restricted vaccine targets derived from the Matrix protein 1 and potentially the non-structural protein and the RNA polymerase catalytic subunit of influenza viruses.
尽管有可用的疫苗,但季节性流感病毒每年仍导致约65万人死亡。CD8 T细胞通常识别来自流感病毒内部结构蛋白和非结构蛋白的肽段,由于它们可以降低感染多种流感毒株后疾病的严重程度,因此是未来疫苗设计的一个有吸引力的途径。CD8 T细胞识别由高度多态的人类白细胞抗原I类分子(HLA-I)呈递的肽段。每个HLA-I变体都有不同的肽结合偏好,这是设计能在广泛人群中引发CD8 T细胞反应的疫苗的一个重大障碍。因此,合理设计CD8 T细胞介导的疫苗需要鉴定受一系列不同HLA分子限制的高免疫原性肽段。
在此,我们评估了通过质谱鉴定并预测与常见的HLA-B*18:01分子结合的六种最近发表的新型流感衍生肽段的免疫原性。
使用CD8 T细胞活化试验和蛋白质生物化学方法,我们发现6种新型肽段中有3种在多个HLA-B18:01个体中具有免疫原性,并证实了它们对HLA-B18:01的限制性。随后,我们比较了CD8 T细胞对先前鉴定的高免疫原性HLA-B18:01限制性NP肽段的反应。利用X射线晶体学,我们解析了呈递免疫原性流感衍生肽段的HLA-B18:01的首个晶体结构。最后,我们剖析了首个针对HLA-B*18:01限制性病原体衍生肽段的TCR库,鉴定了针对四种肽段中每一种的私有和限制性库。
总体而言,这些新型免疫原性肽段的表征提供了额外的源自基质蛋白1以及可能来自流感病毒非结构蛋白和RNA聚合酶催化亚基的HLA-B*18:01限制性疫苗靶点。